



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by *Pseudomonas aeruginosa*: LPC therapeutic effect in combined therapy



Raquel Parra-Millán^{a,1}, Manuel E. Jiménez-Mejías^{a,*,1}, Rafael Ayerbe-Algaba^a, Juan Domínguez-Herrera^a, Caridad Díaz^b, José Pérez del Palacio^b, Jerónimo Pachón^a, Younes Smani^a

^a Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain

^b Fundación Centro De Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Fundación MEDINA, Granada, Spain

ARTICLE INFO

Article history:

Received 24 April 2020

Accepted 15 June 2020

Keywords:

Lysophosphatidylcholine
Combined antimicrobial treatment
Immune response
Peritoneal sepsis model
Pneumonia model
Pseudomonas aeruginosa

ABSTRACT

Introduction: Immune response stimulation may be an adjuvant to antimicrobial treatment. Here, we evaluated the impact of immune response modification by lysophosphatidylcholine (LPC), combined with imipenem or ceftazidime, in murine models of peritoneal sepsis (PS) and pneumonia induced by *Pseudomonas aeruginosa*.

Methods: The imipenem and ceftazidime-susceptible strain (Pa39) and imipenem and ceftazidime-resistant strain (Pa238) were used. Ceftazidime pharmacokinetic and pharmacodynamic parameters were determined. The therapeutic efficacy and TNF- α and IL-10 levels were determined in murine models of PS and pneumonia induced by Pa39 and Pa238 and treated with LPC, imipenem or ceftazidime, alone or in combination.

Results: In the PS model, LPC+ceftazidime reduced spleen and lung Pa238 concentrations (-3.45 and $-3.56 \log_{10}$ CFU/g; $P < 0.05$) to a greater extent than ceftazidime monotherapy, while LPC + imipenem maintained the imipenem efficacy (-1.66 and $-1.45 \log_{10}$ CFU/g; $P > 0.05$). In the pneumonia model, LPC + ceftazidime or LPC + imipenem reduced the lung Pa238 concentrations ($-2.37 \log_{10}$ CFU/g, $P = 0.1$, or $-1.35 \log_{10}$ CFU/g, $P = 0.75$). For Pa39, no statistically significant difference was observed in the PS and pneumonia models between combined therapy and monotherapy. Moreover, LPC + imipenem and LPC+ceftazidime significantly decreased and increased the TNF- α and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies.

Conclusions: These results demonstrate the impact of immune response modification by LPC plus antibiotics on the prognosis of infections induced by ceftazidime-resistant *P. aeruginosa*.

© 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Impacto de la modificación de la respuesta inmunitaria por la lisofosfatidilcolina en la eficacia de la terapia antibiótica en un modelo experimental de sepsis peritoneal y de neumonía por *Pseudomonas aeruginosa*

RESUMEN

Introducción: La estimulación de la respuesta inmunitaria podría ser adyuvante al tratamiento antimicrobiano. En este estudio, hemos evaluado el impacto de la modificación de la respuesta inmunitaria por la lisofosfatidilcolina (LPC), combinada con imipenem ó ceftazidima, en modelos murinos de sepsis peritoneal (SP) y de neumonía por *Pseudomonas aeruginosa* (*P. aeruginosa*).

Palabras clave:

Lisofosfatidilcolina
Tratamiento antimicrobiano combinado
Respuesta inmunitaria

* Corresponding author.

E-mail address: mej-mejias@telefonica.net (M.E. Jiménez-Mejías).

¹ These authors contributed equally to this work.

Modelo de sepsis peritoneal, Modelo de neumonía
Pseudomonas aeruginosa

Métodos: La cepa sensible a imipenem y ceftazidima (Pa39) y la cepa resistente a ambos antibióticos (Pa238) fueron usadas. Los parámetros farmacocinéticos/farmacodinámicos de ceftazidima fueron determinados. La eficacia terapéutica y los niveles de TNF- α and IL-10 fueron determinados en los modelos murinos de SP y de neumonía por Pa39 y Pa238 y tratados con LPC, imipenem o ceftazidima, en monoterapia ó en combinación.

Resultados: En el modelo de SP, LPC + ceftazidima redujo la concentración de Pa238 en el bazo y el pulmón ($-3,45$ y $-3,56$ \log_{10} UFC/g; $p < 0,05$) en comparación con ceftazidima, mientras LPC + imipenem mantuvo la eficacia de imipenem ($-1,66$ y $-1,45$ \log_{10} UFC/g; $p > 0,05$). En el modelo de neumonía, LPC + ceftazidima o LPC + imipenem redujo la concentración de Pa238 en pulmón ($-2,37$ \log_{10} UFC/g, $p = 0,1$ o $-1,35$ \log_{10} UFC/g, $p = 0,75$). Para Pa39, no se observó diferencia estadística significativa entre la terapia combinada y la monoterapia en los modelos de SP y de neumonía. Además, LPC + imipenem y LPC + ceftazidime redujeron y aumentaron los niveles de TNF- α y IL-10, respectivamente, en comparación con los controles no tratados y las monoterapias.

Conclusiones: Estos resultados demuestran el impacto de la modificación de la respuesta inmunitaria por LPC en combinación con antibióticos en el pronóstico de las infecciones por *P. aeruginosa* ceftazidima-resistente.

© 2020 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.

Introduction

Pseudomonas aeruginosa, a ubiquitous microorganism, is one of the most relevant pathogens causing human opportunistic infections.¹ *P. aeruginosa* is a leading cause of severe nosocomial infections, particularly in critically ill and immunocompromised patients.^{2,3} Indeed, *P. aeruginosa* is the top pathogen causing ventilator-associated pneumonia and burn wound infections and is a major cause of nosocomial bacteremia.^{2–4} During the last decade, this pathogen has become increasingly resistant to most antimicrobials, including imipenem and ceftazidim.⁵

An MDR pattern is commonly observed for *P. aeruginosa* clinical isolates, raising the threat of difficult-to-treat infections^{6–8} These MDR isolates are generally susceptible to polymyxins (colistin and polymyxin B) and resistant to imipenem and ceftazidime.⁹ In a study including bacteremic patients affected by *P. aeruginosa*, ceftazidime and imipenem resistance rates were 36.6% and 22.8%, respectively, and a multivariate analysis showed that resistance to both antimicrobial agents is a significant factor associated with mortality.¹⁰

While new beta-lactamases inhibitors, combined with existing antibiotic families, such as ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam, against specific carbapenemases, have recently been developed,¹¹ the retreat of the pharmaceutical sector from new antibiotic development has exacerbated the challenge of widespread resistance and signals a critical need for innovation, for instance, non-antimicrobial approaches and repurposing drugs. All these reasons have made the search for new alternatives to the treatment and control of infections caused by *P. aeruginosa* urgent and necessary.^{5,6} Not killing bacteria, but instead avoiding the infection produced by *P. aeruginosa*, either by immunizing the host or blocking the bacterial virulence factors, could constitute an adjuvant approach to reach new therapeutic goals.

Immune system stimulation by lysophosphatidylcholine (LPC) is one of the most promising approaches. LPC is a major component of the phospholipids. It has been reported to stimulate different immune cells such as monocytes, macrophages, lymphocytes T and neutrophils.^{12–15} Two specific receptors of LPC (GPR4 and G2A) have been described in neutrophils, lymphocytes and fibroblasts.^{16–18} Moreover, LPC is able to increase the release of INF-gama, IL-2 and IL-12, and to reduce the release of TNF-alpha and IL-1 beta in a murine disseminate polymicrobial sepsis.^{16,19} As a result of these events, several studies have showed the involvement of LPC in the recruitment of immune cells,^{19–21} suggesting its possible role in the elimination of prokaryotic cells during infection.

We have successfully demonstrated the efficacy of LPC at 25 mg/kg as a pre-emptive treatment in monotherapy and in combination with colistin, tigecycline or imipenem in experimental models of murine peritoneal sepsis and pneumonia caused by susceptible and MDR *Acinetobacter baumannii*.^{22,23} In addition Miyazaki *et al.* have showed that LPC in combination with gentamycin is active against methicillin-resistant *Staphylococcus aureus*.²⁴ However, no studies have evaluated the therapeutic efficacy of LPC in combination with ceftazidime and imipenem against *P. aeruginosa*.

In this study, we aimed: (i) to evaluate the efficacy of LPC in combination with imipenem or ceftazidime in murine models of peritoneal sepsis and pneumonia caused by susceptible (Pa39) and MDR (Pa238) *P. aeruginosa* strains; and (ii) to determine the impact of immune response modification by LPC in combination with imipenem or ceftazidime in both models of infections caused by both strains.

Materials and methods

Bacterial strains

P. aeruginosa (Pa39), a clinical strain susceptible to ceftazidime and imipenem, was isolated from a blood culture, and MDR *P. aeruginosa* (Pa238), a clinical strain resistant to ceftazidime, imipenem, ciprofloxacin and tobramycin, and harboring the metallo-beta-lactamase VIM-2, was isolated from a blood culture. Both strains were from the REIPI-GEIH 2008 collection.²⁵

Antimicrobial agents and reagents

For the *in vitro* assays, antimicrobials were used as standard laboratory powders: ceftazidime and imipenem (Sigma, Spain). For the *in vivo* experiments, clinical formulations of antimicrobials were used: ceftazidime (Normon, Spain) and imipenem (Merk Sharp and Dohme, Spain). The anesthetic was 5% (w/v) sodium thiopental, which was administered intraperitoneally (i.p.) (B. Braun Medical S.A., Spain).

In vitro susceptibility testing

Minimal inhibitory concentrations (MICs) were determined by broth microdilution assay according to the standard CLSI recommendations,²⁶ which have previously been described.²⁷ *Escherichia coli* ATCC 25922 was used as a control strain.

Animals

Eight-week-old immunocompetent C57BL/6 female mice, weighting 18–20 g (Production and Experimentation Animal Center, University of Seville, Seville, Spain), were used. The animals were housed in regulation cages and given free access to food and water. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals.²⁸ The protocol was approved by the Committee of Ethics for Animal Experiments of the University Hospital of Virgen del Rocío of Seville (2014PI/014).

Antimicrobial pharmacokinetics and pharmacodynamics parameters

Serum LPC and imipenem levels were previously determined by our research group.^{22,23} Serum ceftazidime levels were determined in groups of 30 healthy mice, following single doses of 100 mg/kg i.p. of ceftazidime. In sets of three animals, blood samples were obtained from anesthetized mice from the periorbital plexus at 0, 5, 10, 15, 30, 60, 90, 120, 240, 480 and 1440 min after antimicrobial administration. Concentrations of ceftazidime were measured using HPLC-tandem mass spectrometry (LC-MS/MS).²⁹ The C_{max} in serum, AUC_{0-∞}, t_{1/2}, and T > MIC ratios were obtained by a computer-assisted method.³⁰ The final dosing of free ceftazidime in the *in vivo* experiments was adjusted to achieve a T > MIC of at least ≈40–50% of the dosing interval.³¹

Experimental murine model of peritoneal sepsis

The previously characterized murine peritoneal sepsis model of *A. baumannii* was used.²² Briefly, the animals were inoculated i.p. with 0.5 mL of the minimal lethal dose of 100 (MLD₁₀₀) of the Pa39 or Pa238 strains, mixed 1:1 with 10% porcine mucin (Sigma, Spain). The MLD₁₀₀, lethal dose of 50 (LD₅₀) and lethal dose of 0 (LD₀) were determined by inoculating groups of 6 mice i.p. with decreasing concentrations of *P. aeruginosa* from 7.6 to 3.85 Log CFU/mL for the Pa39 strain, and from 7.8 to 4 Log CFU/mL for the Pa238 strain. The survival of the mice was monitored for 7 days, and these values were determined using the Probit method. LPC therapy was administered as a pretreatment 1 h before bacterial inoculation, and antimicrobial therapy was initiated 4 h after the bacterial inoculation. Groups of 15 mice were randomly ascribed to the following groups: (1) untreated controls (without treatment); (2) LPC administered once at 75 mg/kg i.p. at 1 h before bacterial inoculation; (3) ceftazidime administered i.p. at 100 mg/kg/12 h for 72 h; (4) imipenem administered i.m. at 30 mg/kg/4 h for 24 h; and (5) and (6) the combinations of LPC at 75 mg/kg and ceftazidime at 100 mg/kg/12 h, and imipenem at 30 mg/kg/4 h, respectively. The antimicrobial dosages were chosen after obtaining the PK/PD data.

The mortality was recorded over 24 h (for the imipenem treatment groups) or 72 h (for the ceftazidime treatment group). After the death or the putting down of the mice at the end of the experimental period, aseptic thoracotomies were performed, and blood samples were obtained by a cardiac puncture for qualitative blood cultures. The samples were inoculated in sterile tubes with 1 mL of Luria Bertani (LB) broth and incubated for 24 h at 37 °C, and then 100 µL were plated onto sheep blood agar. The results of the blood cultures are expressed as positive (when ≥1 CFU was present in the plate) or negative. The spleen and lungs were aseptically removed and homogenized (Stomacher 80; Tekmar Co., USA) in 2 mL of sterile NaCl 0.9% solution. Ten-fold dilutions of the homogenized spleen and lungs were plated onto sheep blood agar for quantitative cultures (Log₁₀ CFU/g of spleen or lung).

Experimental murine model of pneumonia

A previously described experimental murine pneumonia model²³ was used to evaluate the efficacy of LPC in monotherapy and in combination with antimicrobial agents against the Pa39 and Pa238 strains. Briefly, the mice were anesthetized by an i.p. injection of 5% (wt/vol) sodium thiopental. They were suspended vertically, and the trachea of each was then cannulated with a blunt-tipped metal needle. The fell of the needle tip against the tracheal cartilage confirmed the intratracheal location. A micro-liter syringe (Hamilton Co., Reno, NV) was used for the inoculation of 50 µL of the MLD100.

The mice remained in a vertical position for 3 min and then in a 30° position, until they awoke. The MLD100 and LD0 were determined by inoculating groups of 6 mice intratracheally with decreasing concentrations of the Pa39 and Pa238 strains from 10 to 9 Log₁₀ CFU/mL and monitoring the survival of the mice for 7 days. The treatment groups were similar to the experimental model of peritoneal sepsis. After the death or putting down of the mice at the end of the experimental period, aseptic thoracotomies were performed, and blood samples for a qualitative blood culture were obtained by a cardiac puncture (data are reported as the number [%] of positive cultures). The lungs were aseptically removed and homogenized as described above for a quantitative culture (data are reported in Log₁₀ CFU/g of the lung).

Cytokine assay

Blood samples were collected from the periorbital plexuses of 72 anesthetized mice, which were infected or not infected with Pa238 at the MLD100 in the peritoneal sepsis and pneumonia models and treated or not with imipenem, ceftazidime, the LPC-imipenem combination or the LPC-ceftazidime combination, as previously described.⁶ The serum levels of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10) were determined in mice at 0, 4, and 8 h post-infection or treatment with imipenem or ceftazidime using an enzyme-linked immunosorbent assay (ELISA) (eBioscience, Spain), following the protocol presented in Figure S1.

Statistical analysis

Differences in the bacterial spleen and lung concentrations (mean ± standard error of the mean (SEM) log CFU/g of tissue) were assessed by an analysis of variance (ANOVA) and *post hoc* Dunnett test. Differences in the blood sterility (%) between groups were compared by an χ^2 test, after normalization determination by the Kolmogorov–Smirnov test. For the mice survival model, a Kaplan–Meier test was performed to determine the difference between mortality rates. A *P*-value of <0.05 was considered significant. The SPSS (version 17.0) statistical package was used (SPSS Inc.).

Results

Antimicrobial susceptibilities

The MICs of imipenem, ceftazidime and LPC for the Pa39 strain were 1, 1, and >8000 mg/L, respectively. The MICs of imipenem, ceftazidime, and LPC for Pa238 were 32, 64, and >8000 mg/L, respectively.

Pharmacokinetic and pharmacodynamic parameters

The pharmacokinetic and pharmacodynamic (PD) data for total imipenem and free ceftazidime are shown in Table S1.




Fig. 1. Mice survival after treatment with LPC in combination with imipenem or ceftazidime in the model of peritoneal sepsis induced by the *P. aeruginosa* Pa39 and Pa238 strains. CTL, control (no treatment); LPC, lysophosphatidylcholine; IMP, imipenem; CFZ, ceftazidime.*: mice mortality was recorded over 24 h in imipenem w/o LPC.

MLD₁₀₀, LD₅₀, and LD₀ of P. aeruginosa

To determine the MLD₁₀₀, LD₅₀, and LD₀ of the Pa39 and Pa238 strains, the murine peritoneal sepsis and pneumonia models were used. In the peritoneal sepsis, the mortality was dependent on the concentration of bacteria in the inoculum (data not shown). The MLD₁₀₀, LD₅₀, and LD₀ of the Pa39 strain were 3.85, 2.57 and <1.81 Log₁₀ CFU/mL, respectively, and the MLD₁₀₀, LD₅₀, and LD₀ of the Pa238 strain were 6.7, 4.65 and <3.08 Log₁₀ CFU/mL, respectively. With respect to the murine pneumonia model, the inoculum of both strains was concentrated to 10 Log₁₀ CFU/mL for each strain to reach 100% of mice mortality. Meanwhile, the LD₀ was 9 Log₁₀ CFU/mL.

Efficacy of LPC and LPC combined treatments in murine peritoneal sepsis model

The efficacy of LPC alone and in combination with imipenem or ceftazidime in the murine peritoneal sepsis model, after inoculation with MLD₁₀₀ of the Pa39 or Pa238 strains is shown in Fig. 1 and Table 1. All treatments, except that with LPC alone, increased the survival rate, compared with the untreated controls, for the Pa39 strain (*P*<0.05). For the Pa238 strain, only LPC plus imipenem increased mice survival, compared with the untreated controls (*P*<0.05) (Fig. 1). Regarding the spleen and lung bacterial loads, the imipenem monotherapy decreased the bacterial loads in ≈7.55 log₁₀ CFU/g (*P*<0.05), for the Pa39 strain, and in 0.5 and

1.5 log₁₀ CFU/g, respectively, for the Pa238 strain, compared with the untreated controls. LPC plus imipenem decreased the bacterial loads in both tissues in ≈8 log₁₀ CFU/g (*P*<0.05), for the Pa39 strain, and in ≈2 log₁₀ CFU/g, for the Pa238 strain, compared with the untreated controls or LPC monotherapy. Moreover, ceftazidime monotherapy decreased the spleen and lung bacterial loads in ≈7.5 and ≈7.2 log₁₀ CFU/g, (*P*<0.05), respectively, for the Pa39 strain, and in 0.5 and 1.5 log₁₀ CFU/g (*P*<0.05), respectively, for the Pa238 strain, compared with the untreated controls. LPC plus ceftazidime decreased the spleen and lung bacterial loads in ≈8 log₁₀ CFU/g (*P*<0.05), for the Pa39 strain, and in ≈4.5 and ≈5 log₁₀ CFU/g (*P*<0.05), respectively, for the Pa238 strain, compared with the untreated controls or LPC monotherapy (Table 1). With respect to bacteremia induced by the Pa39 strain, the imipenem and ceftazidime monotherapies reduced it to 0%, compared with the untreated controls. For the Pa238 strain, only LPC plus imipenem and LPC plus ceftazidime reduced the bacteremia to 93.33% and 53.33% (*P*<0.05), respectively, compared with the untreated controls (Table 1).

Efficacy of LPC and LPC combined treatments in murine experimental model of pneumonia

The efficacy of LPC alone and in combination with imipenem or ceftazidime was tested in the murine pneumonia model after an inoculation of 10 Log₁₀ CFU/mL (MLD₁₀₀) of each strain (Fig. 2 and Table 2). For both strains, treatment with LPC plus imipenem

Table 1

Therapeutic effect of LPC in combination with imipenem or ceftazidime in a murine peritoneal sepsis model of *P. aeruginosa*.

	Treatment	N	Log ₁₀ CFU/g of spleen (mean ± SEM)	Log ₁₀ CFU/g of lungs (mean ± SEM)	Positive blood cultures (%)
Pa39	CTL	8	8.04 ± 0.06	7.78 ± 0.10	100
	LPC	8	8.57 ± 0.09 ^a	7.89 ± 0.07	100
	IMP	14	0.54 ± 0.29 ^{a,b}	0.14 ± 0.14 ^{a,b}	0 ^{a,b}
	LPC+IMP	15	0.17 ± 0.17 ^{a,b}	0.14 ± 0.14 ^{a,b}	0 ^{a,b}
	CFZ	14	0.49 ± 0.49 ^{a,b}	0.49 ± 0.49 ^{a,b}	0 ^{a,b}
	LPC+CFZ	15	0 ^{a,b}	0 ^{a,b}	0 ^{a,b}
Pa238	CTL	8	8.91 ± 0.29	8.42 ± 0.35	100
	LPC	8	8.68 ± 0.09	8.06 ± 0.21	100
	IMP	14	8.40 ± 0.11	7.78 ± 0.10	100
	LPC+IMP	15	6.74 ± 0.74	6.33 ± 0.7	93
	CFZ	14	7.67 ± 0.21 ^{a,b}	6.90 ± 0.24 ^{a,b}	100
	LPC+CFZ	15	4.22 ± 0.58 ^{a,b,c}	3.34 ± 0.59 ^{a,b,c}	53 ^{a,b,c}

CTL, untreated controls (no treatment); LPC, lysophosphatidylcholine; IMP, imipenem; CFZ, ceftazidime.

^a Compared to the untreated controls, *P*<0.05.

^b Compared to LPC, *P*<0.05.

^c Compared to the IMP or CFZ, *P*<0.05—concentrations that have been shown to be effective for ≥50% and ≥90% of the isolates tested, respectively.




Fig. 2. Mice survival after treatment with LPC in combination with imipenem or ceftazidime in a model of pneumonia induced by the *P. aeruginosa* Pa39 and Pa238 strains. CTL, control (no treatment); LPC, lysophosphatidylcholine; IMP, imipenem; CFZ, ceftazidime.*: mice mortality was recorded over 24 h in imipenem w/o LPC.

Table 2
Therapeutic effect of LPC in combination with imipenem or ceftazidime in a murine pneumonia model of *P. aeruginosa*.

	Treatment	N	Log ₁₀ CFU/g of lungs (mean ± SEM)	Positive blood culture (%)
Pa39	CTL	8	9.44 ± 0.19	100
	LPC	13	8.41 ± 0.72	92
	IMP	15	4.57 ± 0.56 ^{a,b}	47 ^{a,b}
	LPC + IMP	15	3.53 ± 0.60 ^{a,b}	7 ^{a,b,c}
	CFZ	14	4.96 ± 0.93 ^{a,b}	64
	LPC + CFZ	14	4.42 ± 0.93 ^{a,b}	43 ^{a,b}
Pa238 (24 h)	CTL	8	8.38 ± 0.73	100
	LPC	8	8.74 ± 0.83	100
	IMP	14	7.30 ± 0.68	57 ^{a,b}
	LPC + IMP	14	5.95 ± 0.83 ^a	21 ^{a,b}
Pa238 (72 h)	CTL	8	10.84 ± 0.07	100
	LPC	15	7.7 ± 1.11	73
	CFZ	15	9.58 ± 0.53	93
	LPC + CFZ	15	7.21 ± 0.79 ^a	53 ^{a,c}

CTL, untreated controls (no treatment); LPC, lysophosphatidylcholine; IMP, imipenem; CFZ, ceftazidime.

^a Compared to the untreated controls, *P* < 0.05.

^b Compared to the LPC, *P* < 0.05.

^c Compared to the IMP or CFZ, *P* < 0.05.

or LPC plus ceftazidime reduced mortality to 7–64%, compared with the untreated controls (Fig. 2). Regarding the bacterial lung load, imipenem or ceftazidime decreased the Pa39 and Pa238 strains by 4.87 (*P* < 0.05) and 1.08 log₁₀ CFU/g or 4.48 (*P* < 0.05) and 1.26 log₁₀ CFU/g, respectively, compared with the untreated controls. LPC plus imipenem decreased the bacterial lung load of the Pa39 and Pa238 strains by 5.91 and 4.89 log₁₀ CFU/g (*P* < 0.05), or 4.88 (*P* < 0.05) and 2.79 log₁₀ CFU/g, respectively, compared with the untreated controls or LPC monotherapy. LPC plus ceftazidime decreased the bacterial lung load of the Pa39 and Pa238 strains by 5.02 (*P* < 0.05) and 3.63 log₁₀ CFU/g, or in 3.99 (*P* < 0.05) and 0.49 log₁₀ CFU/g, respectively, compared with the untreated

controls or LPC monotherapy (Table 2). With respect to bacteremia, LPC plus imipenem and LPC plus ceftazidime reduced both strains of it to ≈50–93%, compared with the untreated controls, and to ≈20–40%, compared with the antimicrobial monotherapies (*P* < 0.05) (Table 2).

Cytokines production

The effects of different treatments on cytokine production in models of peritoneal sepsis and pneumonia induced by the Pa238 strain were evaluated (Fig. 3). In the peritoneal sepsis model, the imipenem and ceftazidime monotherapies non-significantly




Fig. 3. Experimental models of the cytokine production after MDR *P. aeruginosa*-induced murine peritoneal sepsis (A) and pneumonia (B). The levels of TNF- α , IL-6 and IL-10 in serum were determined from 0 to 8 h for mice inoculated with the Pa238 strain and treated or not treated with imipenem, ceftazidime, the LPC-imipenem combination or the LPC-ceftazidime combination. Representative results are shown, and the data are presented as the means. CTL, untreated controls (no treatment); LPC, lysophosphatidylcholine; IMP, imipenem; CFZ, ceftazidime. * and †: compared to CTL, $P < 0.05$; #: compared to IMP or CFZ, $P < 0.05$.

increased the release of TNF- α to 5207.61 ± 2859.34 pg/mL and 5232.59 ± 3905.02 pg/mL, respectively, and decreased the release of IL-10 to 1002.25 ± 405.43 pg/mL ($P < 0.05$) and 761.96 ± 182.09 pg/mL ($P < 0.05$), respectively, at 8 h (time that corresponds to 4 h of imipenem and ceftazidime treatment), compared with the untreated controls at 8 h: 1900.60 ± 638.01 pg/mL for TNF- α , and 2423.29 ± 607.45 pg/mL for IL-10. Meanwhile, LPC plus imipenem and LPC plus ceftazidime combinations decreased the release of TNF- α to 62.7 ± 14.3 pg/mL ($P < 0.05$) and 63.53 ± 19.42 pg/mL ($P < 0.05$), respectively, and increased the release of IL-10 to 4950.25 ± 202.67 pg/mL ($P < 0.05$) and 3829.5 ± 1760.76 pg/mL ($P < 0.05$), respectively, at 8 h, compared with the imipenem and ceftazidime monotherapies: 5207.61 ± 2859.34 pg/mL and 5232.59 ± 3905.02 pg/mL, respectively, for TNF- α , and 1002.25 ± 405.43 pg/mL and 761.96 ± 182.09 pg/mL for IL-10, respectively. In the case of IL-6, imipenem and ceftazidime monotherapies increased the release of IL-6 to 2274.4 ± 113.51 pg/mL ($P = 0.018$) and $2148.58 \pm 3.4.03$ pg/mL ($P = 0.053$), respectively, at 8 h, compared with the control group: 748.2 ± 362.84 pg/mL. Meanwhile, LPC plus imipenem and LPC plus ceftazidime combinations induced a similar release of IL-6, compared with the imipenem and ceftazidime monotherapies (Fig. 3A).

In the pneumonia model, similar results concerning the effect of the imipenem and ceftazidime monotherapies and the LPC plus imipenem and LPC plus ceftazidime combinations on the serum TNF- α and IL-10 levels at 8 h post-bacterial inoculation were observed. The LPC plus imipenem and LPC plus ceftazidime combinations decreased the release of TNF- α to 150.73 ± 52.7 pg/mL ($P < 0.05$) and 54.77 ± 3.21 pg/mL ($P < 0.05$), respectively, and increased the release of IL-10 to 1648 ± 969.97 pg/mL ($P < 0.05$) and 809.54 ± 130.07 pg/mL ($P < 0.05$), respectively, compared with the imipenem and ceftazidime monotherapies: 1007.17 ± 267.19 pg/mL and 1564.55 ± 101.84 pg/mL, respectively,

for TNF- α , and 35.33 ± 14.33 pg/mL and 44.75 ± 7.7 pg/mL, respectively, for IL-10. In the case of IL-6, the imipenem and ceftazidime monotherapies non-significantly increased the release of IL-6 to 929.42 ± 188.11 pg/mL and 1360.49 ± 475.24 pg/mL, respectively, at 8 h, compared with the control group: 855.40 ± 459.13 pg/mL. Moreover, the LPC+imipenem and LPC+ceftazidime combinations increased the release of IL-6 to 3130.40 ± 558.14 pg/mL ($P = 0.043$) and 1884.62 ± 68.13 pg/mL ($P = 0.212$), respectively, at 8 h, compared with the imipenem and ceftazidime monotherapies: 929.42 ± 188.11 pg/mL and 1360.49 ± 475.24 pg/mL, respectively (Fig. 3B).

Importantly, the imipenem and ceftazidime treatments in healthy mice did not significantly change the release of TNF- α , IL-6, and IL-10 at 4 and 8 h, when compared with mice that did not receive antibiotic treatments (Fig. 3).

Discussion

As expected, in the pneumonia model of the MDR strain, no significant increase of mice survival and decrease of bacterial burden in tissues were observed with imipenem or ceftazidime due to resistance to both antimicrobials; however, the treatment with LPC plus imipenem or LPC plus ceftazidime reduced the bacterial loads and bacteremia by ≈ 1.35 – 2.35 log₁₀ CFU/g and 50%, respectively, compared with the antimicrobial monotherapies, and survival increased slightly. Similar data have been observed with LPC plus imipenem or LPC plus tigecycline in a model of *A. baumannii* resistant to imipenem and tigecycline pneumonia.²³

In a peritoneal sepsis model of the MDR Pa238 strain, LPC plus ceftazidime did not improve survival at 72 h, even if the bacterial burden in tissue was lower than in untreated controls and the ceftazidime monotherapy. The analysis of survival at 24 h showed a mortality of 27% (4 out of 15 mice), a mortality similar to the 20% at 24 h with LPC plus imipenem. These data suggest that LPC,

administered in one dose before the inoculation, only reduced early mice mortality. In keeping with this result, in 2013, Jacqueline *et al.* demonstrated that in a murine experimental model of pneumonia induced by *P. aeruginosa*, the bacterial burden in spleen and lung, after treatment with ceftazidime, was 2.74 and 4.74 Log₁₀ CFU/mL, respectively, and the mortality reached 80%.³²

It is important to note that ceftazidime in combination with LPC against the MDR Pa238 strain in a peritoneal sepsis model did not improve mice survival to a greater extent than in the ceftazidime and LPC monotherapies or control animals. Meanwhile, ceftazidime combined with LPC increased the mice survival in the pneumonia model. In the case of imipenem, the combination with LPC against MDR Pa238 strain has less improved the mice mortality in pneumonia model than in peritoneal sepsis model, according with the results with imipenem monotherapy, which reached 83% in the pneumonia model vs. 0% in the peritoneal sepsis model. Evidence supports this data, in which we have demonstrated previously that imipenem in combination with LPC against MDR *A. baumannii* Ab186 strain, resistant to imipenem, has improved the mice survival until 100% in the pneumonia model vs. 33.33% in the peritoneal sepsis model, also in according with the survival with imipenem monotherapy (100% vs. 0%, respectively).²³ As for the *A. baumannii* ATCC 17978 strain, we found that the LPC monotherapy in the peritoneal sepsis model only increased 40% of mice survival vs. the 68% observed in the pneumonia model.²² In the same way, rifampicin combined with colistin improved the mice survival in the model of peritoneal sepsis induced by carbapenemase-producing *Klebsiella pneumoniae* to a lesser extent than in the pneumonia model (unpublished data).

Furthermore, we showed that LPC monotherapy in the model of peritoneal sepsis induced by the susceptible Pa39 strain and MDR Pa238 strain had no significantly increased mice survival and decreased bacterial burden in tissues. In contrast, in the model of pneumonia induced by the susceptible Pa39 and MDR Pa238 strains, we observed that LPC monotherapy for 72 h reduced the bacterial loads in the lungs by 1.03 and 3.14 log₁₀ CFU/g, respectively. This difference in the results between both experimental models of infections is due to the severity of the peritoneal sepsis model, in which the sepsis was defined as the result of a dysregulated systemic inflammatory response syndrome in the presence of infection, accompanied by major organ failure and death.³³ This infection severity does not allow LPC in monotherapy to significantly reduce the bacterial loads of both strains in tissues. Moreover, the difference in the effect of LPC on both strains in the pneumonia model has been observed, and this was more present in the case of the MDR Pa238 strain than in the case of the susceptible Pa39 strain. This is due to the difference in the virulence degree of both strains. In the pneumonia model, the susceptible Pa39 strain caused 100% of mice mortality in the first 24 h, in contrast with the MDR strain, which caused only 37% of mice mortality in the first 24 h. We can suggest that in murine models of *P. aeruginosa*, it is necessary to administer a LPC dose higher than 25 mg/kg to significantly improve survival.

For other pathogens, such as *Staphylococcus aureus*, Miyazaki *et al.* showed, *in vitro*, that LPC can enhance the antimicrobial effects of gentamicin against methicillin-resistant *S. aureus* (MRSA), suggesting the application of LPC as a beneficial additive to topical antibiotics for superficial skin infections.²⁴ The mode of action of LPC is different, depending on the pathogen species. In Gram positive bacteria, LPC can directly induce MRSA killing by interacting with cytoplasmic membranes, inducing membrane depolarization and increasing membrane permeability.²⁴ In Gram negative bacteria, LPC did not directly affect these bacteria due to their outer membrane, which prevents the interaction between the LPC and bacterial cytoplasmic membrane.^{16,22,23} The beneficial effects of LPC alone against *E. coli* have been associated with

the activation of hydrogen peroxide by neutrophils, and with the induction of phagocytosis by macrophages through the activation of AMP-activated protein Kinase.^{16,34} In LPC combined with antibiotic treatments against *P. aeruginosa* infections, these pathways can be suggested as some of the modes of action of LPC as an adjunct to the antibiotic effect. Besides, LPC alone and in combination with antibiotic treatment against *E. coli* and *A. baumannii* have previously been associated with the modulation of inflammation, such as the upregulation of monocyte chemotactic protein-1 and pro- and anti-inflammatory cytokines release.^{12,16,22,23} Interestingly, comparing the effect of the pro-inflammatory cytokine, TNF- α , with that of the combination of LPC plus imipenem or LPC plus ceftazidime, at 8 h post-bacterial inoculation, the treatments significantly reduced the TNF- α levels by 83- or 82-fold, respectively, in the model of peritoneal sepsis induced by the MDR strain. In contrast, these reductions were lower in the pneumonia model: 7- or 28-fold with LPC plus imipenem or LPC plus ceftazidime, respectively. These differences in the anti-inflammatory effect of LPC in both models could be the cause of the different results in terms of mice survival. These data are in accordance with the previously reported immunomodulatory effects of LPC.^{16,22} It is important to mention that the immune response, developed in mice treated with LPC and ceftazidime and infected by the Pa39 strain in the peritoneal sepsis model, can help to prevent re-infection by the same strain 7 days after the end of the treatment (data not shown). These data allowed us to suggest that LPC in combination with antibiotics should be able to induce immune response memory to prevent reinfection. More studies are needed to decipher this effect.

Some studies have already been performed to control infections caused by *P. aeruginosa* using small peptides or molecules with immunomodulatory properties. Among them, [E6k,D9k] hymenochirin-1B³⁵ presented high antibacterial activities and immunomodulatory properties *in vitro*. LL-37, a cationic peptide of the cathelicidins family, exhibited significant antimicrobial activity against *P. aeruginosa*.³⁶

As demonstrated in this study, LPC, both as a preemptive therapy or in combination with antimicrobial agents, has shown promising *in vivo* results in severe experimental models of infections induced by *A. baumannii*^{22,23} and *P. aeruginosa*. It is worth noting that the model used in this study was designed to prevent the establishment of infection, following bacterial inoculum. However, caution is needed, and further extensive *in vivo* studies have to be performed to confirm the potential use of these adjuvants, including LPC, as true therapeutic alternatives. The present study has some limitations regarding the LPC treatments regimens. We believe that the next steps in this research are: (i) to determine whether multiple doses of LPC, given as a treatment in combination with antimicrobial agents, following the establishment of an infection induced by *P. aeruginosa*, can improve the preemptive effect of LPC; (ii) to evaluate the therapeutic efficacy of LPC in combination with antibiotics against other clinical isolates of *P. aeruginosa*; and (iii) to use BALB/c mice as another animal model, since BALB/c mice are Th2-biased, while C57BL/6 mice are Th1-biased. Completing these steps are required in order to consider this adjuvant treatment in future clinical trials.

Funding

This study was supported by the Instituto de Salud Carlos III, Proyectos de Investigación en Salud (grant PI13/01744, PI16/01306), and by Consejería de Innovación, Ciencia y Empresa (P11-CTS-6317).

Younes Smani is supported by the Subprograma Miguel Servet Tipo I from the Ministerio de Economía y Competitividad of Spain (CP15/01358). The MEDINA authors disclosed the receipt of financial support from Fundación MEDINA, a public-private

partnership of Merck Sharp & Dohme de España S.A./Universidad de Granada/Junta de Andalucía.

Conflict of interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgements

We thank Dr. Antonio Oliver for the kind gift of the *Pseudomonas aeruginosa* strains Pa39 and Pa238.

Part of this study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria 2017.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.eimc.2020.06.002.

References

- Gellatly SL, Hancock REW. *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. *Pathog Dis*. 2013;67:159–73.
- Kang C, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. *Pseudomonas aeruginosa* bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. *Clin Infect Dis*. 2003;37:745–51.
- Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, et al. Epidemiology and outcome of *Pseudomonas aeruginosa* bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. *Arch Intern Med*. 1996;156:2121–6.
- Vincent JL. Nosocomial infections in adult intensive-care units. *Lancet*. 2003;362:2068–77.
- European Centre for Disease Prevention and Control. Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections; 2014. <http://dx.doi.org/10.2903/j.efsa.2015.4329>, *Ecdc*. <http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf> [accessed 01.07.16].
- Ali Z, Mumtaz N, Naz SA, Jabeen N, Shafique M. Multi-drug resistant *Pseudomonas aeruginosa*: a threat of nosocomial infections in tertiary care hospitals. *J Pak Med Assoc*. 2015;65:12–6.
- Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter retrospective study of *Pseudomonas aeruginosa* nosocomial pneumonia: impact of multidrug resistance. *Crit Care*. 2015;19:2019.
- Kaye KS, Pogue JM. Infections caused by resistant gram-negative bacteria: epidemiology and management. *Pharmacotherapy*. 2015;35:949–62.
- El Solh AA, Alhajhusain A. Update on the treatment of *Pseudomonas aeruginosa* pneumonia. *J Antimicrob Chemother*. 2009;64:229–38.
- Joo EJ, Kang CI, Ha YE, Kang SJ, Park SY, Chung DR, et al. Risk factors for mortality in patients with *Pseudomonas aeruginosa* bacteremia: clinical impact of antimicrobial resistance on outcome. *Microb Drug Resist*. 2011;17:305–12.
- Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? *Clin Microbiol Infect*. 2017;23:704–12.
- Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. *Proc Natl Acad Sci USA*. 1988;85:2805–9.
- Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, et al. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. *J Biol Chem*. 1994;269:31430–5.
- Asaoka Y, Oka M, Yoshida K, Sasaki Y, Nishizuka Y. Role of lysophosphatidylcholine in T-lymphocyte activation: involvement of phospholipase A in signal transduction through protein kinase C. *Proc Natl Acad Sci USA*. 1992;89:6447–51.
- Nishioka H, Horiuchi H, Arai H, Kita T. Lysophosphatidylcholine generates superoxide anions through activation of phosphatidylinositol 3-kinase in human neutrophils. *FEBS Lett*. 1998;441:63–6.
- Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. *Nat Med*. 2004;10:161–7.
- Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. *Science*. 2001;293:702–5.
- Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, et al. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. *J Biol Chem*. 2001;276:41325–35.
- Mesquita RD, Carneiro AB, Bafica A, Gazos-Lopes F, Takiya CM, Souto-Padron T, et al. *Trypanosoma cruzi* infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. *Infect Immun*. 2008;76:5543–52.
- Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T Cell chemotaxis to lysophosphatidylcholine through the G2A receptor. *Proc Natl Acad Sci USA*. 2004;101:245–50.
- Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, et al. Unfolding the pathophysiological role of bioactive lysophospholipids. *Curr Drug Targets Immun Endocr Metabol Disord*. 2003;3:23–32.
- Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J. Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2015;59:3920–4.
- Parra Millán R, Jiménez-Mejías ME, Sánchez Encinales V, Ayerbe Algaba R, Gutiérrez Valencia A, Pachón Ibáñez ME, et al. Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against *Acinetobacter baumannii* in experimental murine peritoneal sepsis and pneumonia models. *Antimicrob Agents Chemother*. 2016;60:4464–70.
- Miyazaki H, Midorikawa N, Fujimoto S, Miyoshi N, Yoshida H, Matsumoto T. Antimicrobial effects of lysophosphatidylcholine on methicillin-resistant *Staphylococcus aureus*. *Ther Adv Infect Dis*. 2017;4:89–94.
- Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in *Pseudomonas aeruginosa* bloodstream infections. *Antimicrob Agents Chemother*. 2012;56:1265–72.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement. Document M100-S24. Wayne, PA: CLSI; 2014.
- Smani Y, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Martí S, Vila J, et al. *In vitro* and *in vivo* reduced fitness and virulence in ciprofloxacin-resistant *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2012;18:E1–4.
- National Research Council. Guide for the care and use of laboratory animals: eighth edition. Washington, DC: National Academies Press; 2011.
- Ye G, Cai X, Wang B, Zhou Z, Yu X, Wang W, et al. Simultaneous determination of vancomycin and ceftazidime in cerebrospinal fluid in craniotomy patients by high-performance liquid chromatography. *J Pharm Biomed Anal*. 2008;48:860–5.
- Usansky JL, Desai A, Tang-Liu D. PK functions for microsoft excel. Allergan, Irvine, CA: Department of Pharmacokinetics and Drug Metabolism; USA; 2012. <https://www.boomer.org/pkin/soft.html>
- Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis*. 1998;26:1–10.
- Jacqueline C, Roquilly A, Desessard C, Boutoille D, Broquet A, Le Mabecque V, et al. Efficacy of ceftolozane in a murine model of *Pseudomonas aeruginosa* acute pneumonia: *In vivo* antimicrobial activity and impact on host inflammatory response. *J Antimicrob Chemother*. 2013;68:177–83.
- Nemzek JA, Hugunin KMS, Opp MR. Modeling sepsis in the laboratory: merging sound science with animal well-being. *Comp Med*. 2008;58:120–8.
- Quan H, Hur YH, Xin C, Kim JM, Choi J, Kim MY, et al. Stearoyl lysophosphatidylcholine enhances the phagocytic ability of macrophages through the AMP-activated protein kinase/p38 mitogen activated protein kinase pathway. *Int Immunopharmacol*. 2016;39:328–34.
- Mechkarska M, Prajeep M, Radosavljevic GD, Jovanovic IP, Al Baloushi A, Sonnevend A, et al. An analog of the host-defense peptide hymenochirin-1B with potent broad-spectrum activity against multidrug-resistant bacteria and immunomodulatory properties. *Peptides*. 2013;50:153–9.
- Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proc Natl Acad Sci USA*. 1998;8:9541–6.